Mogamulizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | CCR4 |
| Clinical data | |
| Trade names | Poteligeo |
| Routes of administration |
Intravenous |
| ATC code | |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| Chemical and physical data | |
| Formula | C6520H10072N1736O2020S42 |
| Molar mass | 146.44 kg/mol |
  (what is this?)
|
|
Mogamulizumab (USAN; trade name Poteligeo) is a humanized monoclonal antibody targeting CC chemokine receptor 4 (CCR4). It was approved in Japan in 2012 for the treatment of relapsed or refractory adult T-cell leukemia/lymphoma.
Mogamulizumab was developed by Kyowa Hakko Kirin Co., Ltd. It has also been licensed to Amgen for development as a therapy for Asthma.
In 2016 it was in phase 1 clinical trials in combination with utomilumab (PF-05082566) for solid cancers.
...
Wikipedia